Search Results for: vertex

ViaCyte purchase puts Vertex in driver’s seat on stem cells for diabetes

Doug Melton, Vertex, ViaCyte

When I’m asked about the most promising areas of stem cell clinical research, cell therapy for type I diabetes is near the top including work by a biotech called ViaCyte. Other firms are in the mix too, boosting the overall odds of success in the coming decade. It’s really that promising even though there are …

ViaCyte purchase puts Vertex in driver’s seat on stem cells for diabetes Read More »

Weekly reads: neural stem cells, CRISPR brain, Vertex, cytoplasm surprise

neural stem cells

Some people consider the brain to be equivalent to a living computer and in that sense it’s too bad that computers don’t have the equal of neural stem cells to help them fix themselves. Is the internet one big neural network-like web? There was a quake in the stem cell internet as CIRM’s main website …

Weekly reads: neural stem cells, CRISPR brain, Vertex, cytoplasm surprise Read More »

Weekly reads: Vertex hold, new type of cell division in fish, CAR-T

zebrafish cell division

I remember the first time I ever witnessed human cell division first hand and it was really excitement. I was working as a part-time tech in the Lane Lab at UC San Diego School of Medicine. We studied heart disease and grew human umbilical cord endothelial cell cultures. It was striking to see a plate …

Weekly reads: Vertex hold, new type of cell division in fish, CAR-T Read More »

Vertex upbeat on 1st stem cell therapy for diabetes trial participant

“While still early, these results support the continued progression of our VX-880 clinical studies, as well as future studies using our encapsulated islet cells, which hold the potential to be used without the need for immunosuppression,” said Bastiano Sanna, Ph.D., executive vice president and chief of cell and genetic therapies at Vertex.

It’s hard in the cell therapy field not to get excited even with bits of seemingly encouraging news but with N=1 reports we have to be very cautious and that’s the case with news from Vertex on their 1st stem cell therapy for diabetes trial participant. Vertex stem cell therapy for diabetes VX-880: N=1 This …

Vertex upbeat on 1st stem cell therapy for diabetes trial participant Read More »

Weekly stem cell reads: space, plagiarism, HIV, diabetes, more

blood stem cell biology

I took a cross-country road trip earlier this month that was pretty amazing and barely thought about stem cell research for the first time in years. We did run across one stem cell clinic in Florida by accident. I’ll write about that trip soon, but first we have our weekly reads including some very cool …

Weekly stem cell reads: space, plagiarism, HIV, diabetes, more Read More »

In big shift Dr. Robert Lanza exits Astellas

Dr. Robert Lanza

The recent news of Vertex Pharma buying small stem cell biotech ViaCyte and Doug Melton moving to Vertex brought to mind an old stem cell biotech called Advanced Cell Technology (ACT) and its leader, stem cell biologist Dr. Robert Lanza. Years ago, big pharma firm Astellas bought ACT and Lanza moved to be a leader of regenerative …

In big shift Dr. Robert Lanza exits Astellas Read More »

Overplaying N=1 in the stem cell therapy world

stem cell therapy, star patient

The regular emails and phone calls I get from patients asking questions about stem cell therapy are a powerful reminder of the fact that research in our field can be very personal. Sometimes individuals who receive experimental stem cell therapy (or other cell therapies) and seem to have a positive outcome can end up becoming …

Overplaying N=1 in the stem cell therapy world Read More »

Weekly reads: Melton leaves Harvard, Fuji, BBC blunder, stem cell niche, more

Senolytics restore the stem cell niche in the brains of mice. Fatt, et al. Stem Cell Reports 2022.

Sometimes a post here on The Niche (named after the stem cell niche) sparks a debate between expert stem cell researchers and often that gives much more depth to a topic. Such was the case with my post this week on where things stand with stem cell therapy for heart disease. It led to a …

Weekly reads: Melton leaves Harvard, Fuji, BBC blunder, stem cell niche, more Read More »

16 predictions for stem cells & regenerative medicine in 2022

regenerative medicine, stem cells 2021

The last few years in the stem cell and regenerative medicine arena have been complicated in many ways. Variables like surging stem cell clinics and COVID have made predictions harder.  Even so, trying to make predictions is useful and it’s fun to go over past year’s predictions. You can see my scorecard on my 2021 …

16 predictions for stem cells & regenerative medicine in 2022 Read More »

Top stem cell stories of 2021: COVID, diabetes, human embryos, clinics in court

regenerative medicine, stem cells 2021

The past year was all over the place for the stem cell and regenerative medicine field. As you can see in my scoring of my 21 predictions for 2021, quite a few things were surprises in terms of what did and didn’t happen. Here’s an overview of the top stories of the year in our …

Top stem cell stories of 2021: COVID, diabetes, human embryos, clinics in court Read More »